SAGE THERAPEUTICS INC (SAGE) Stock News
NASDAQ:SAGE - Nasdaq - US78667J1088 - Common Stock
SAGE Latest News and Analysis
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.
Noteworthy Monday Option Activity: SAGE, AVDL, VRT
These stocks are moving in today's session
Let's take a look at the stocks that are in motion in today's session.
Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In
The two companies have collaborated since 2020 on the depression drug Zurzuvae, approved in 2023 by the FDA for treating postpartum depression.
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts
Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression.
Here are the top movers in Monday's session, showcasing the stocks with significant price changes.
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Gapping stocks in Monday's session
Let's have a look at what is happening on the US markets on Monday. Below you can find the gap up and gap down stocks in today's session.
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
On Friday, Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share. The Sage Board of Directors will carefully review and evaluate Biogen’s proposal. Also Read: After Failed Alzheimer’s Study, Sage Therapeutics’ Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder In November 2020, Biogen and Sage T
Stay updated with the stocks that are on the move in today's pre-market session.
Monday's pre-market session: top gainers and losers
Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025
First Week of SAGE January 2026 Options Trading
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) should contact The Gross Law Firm about pending Class Action - SAGE
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE). Shareholders who purchased shares of...
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit
/PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12,...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAGE
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE) and...
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sage Therapeutics, Inc. ("Sage" or the...
Faruqi & Faruqi Reminds Sage Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - SAGE
Sage Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGE
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sage Therapeutics, Inc. ("Sage Therapeutics" or the "Company") (NASDAQ: SAGE) of a class action...
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit
/PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12,...
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sage Therapeutics, Inc. ("Sage" or the...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAGE
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE) and...